Company: SNY
Filing Date: 2025-02-13
Form Type: 20-F
Source: 0001121404-25-000010
Chunk: 438

Company: Sanofi
Filing Date: 2025-02-13
Form: 20-F
Chunk 438
---
                      -257 |                             30 |                      -120 |                             46 | -166 |

D.21. Off balance sheet commitments

The off balance sheet commitments presented below are shown at their nominal value.

D.21.1. Off balance sheet commitments relating to operating activities

Off balance sheet commitments relating to Sanofi ’s operating activities, not including as of December 31, 2024 the commitments

of the Opella held-for-sale operation, comprise the following:

| December 31, 2024                                                                                                       |       | Payments due by period |             |             |                  |
|:------------------------------------------------------------------------------------------------------------------------|------:|-----------------------:|------------:|------------:|-----------------:|
| (€ million)                                                                                                             | Total |        Less than1 year | 1 to3 years | 3 to5 years | More than5 years |
| Leases with a term of less than 12 months, low value asset leases and leasecontracts committed but not yet commenced(a) |   554 |                     28 |          34 |          41 |              451 |
| Irrevocable purchase commitments(b)                                                                                     |       |                        |             |             |                  |
| •given(c)                                                                                                               | 3,683 |                  1,152 |       1,195 |         442 |              894 |
| •received                                                                                                               |  -391 |                   -288 |         -96 |          -7 |                — |
| Research and development license agreements - commitments given                                                         |       |                        |             |             |                  |
| •commitments related to R&D and other commitments(d)                                                                    |    84 |                     42 |          29 |           6 |                7 |
| •contingent milestone payments in connection with developmentprograms in progress(e)                                    | 4,230 |                    941 |         635 |         470 |            2,184 |
| Total - net commitments given                                                                                           | 8,160 |                  1,875 |       1,797 |         952 |            3,536 |

(a) Includes the variable portion of future lease payments not recognized as lease liabilities as of December 31, 2024 ; the equivalent amount of these

commitments as of December 31, 2023 was € 221 million.

During 2023 , Sanofi signed a 15-year lease which will take effect in 2025 and to which Sanofi